If you have been diagnosed with prolactinoma, the PROMISE survey wants to hear your experiences of symptoms, treatment and living with this condition.
What is the PROMISE survey?
The PROMISE survey is a global study looking into treatment experiences of people with prolactinoma. The study is being run by researchers from the University Hospital Basel, which is based in Switzerland.
Prolactinomas are benign (non-cancerous) tumours of the pituitary gland that cause the pituitary gland to make higher than normal levels of prolactin. Often, this is treated with dopamine agonists. Dopamine agonists are a type of drug that mimic the action of dopamine in the brain. These treatments are usually effective but some patients experience side effects, or relapse after stopping medication. Surgery is another treatment options and may offer long-term remission in some cases.
This survey aims to compare real-life experiences with both treatment options – medication and surgery – including their effectiveness, side effects, and impact on quality of life.
Who can take part?
Anyone who has been diagnosed with prolactinoma is able to take part in this survey, regardless of whether you are currently on treatment or not. The survey is completely anonymous and takes around 10 to 15 minutes to complete.
The survey is available in the following languages: English, German, Spanish and Italian.
Why is this survey important?
Your voice matters. By sharing your experience, you help improve future care and highlight what matters most to patients. Over 100 people have already taken part — we hope you will too!
If you have any questions, please feel free to contact the survey organiser, Dr Cihan Atila. You can reach them by emailing [email protected]
